KR100505780B1 - Healthy food composition having efficacy of anti-diabetic and its process - Google Patents

Abstract

The present invention relates to a health food composition having an anti-diabetic activity, and is a novel health food composition containing phosphorus mugwort, lettuce, maize, beetles, and Schizandra chinensis extract as main ingredients in addition to chaga extract.

Description

Healthy food composition having antidiabetic activity and its preparation method {Healthy food composition having efficacy of anti-diabetic and its process}

The present invention relates to a health food composition having a newly configured anti-diabetic activity, and more particularly, to an antidiabetic method of ultrasonic composition for facilitating extraction of physiologically active substances from chaga and a chaga extract obtained therefrom. The present invention relates to a health food composition having activity and a method for producing the same.

Given that Koreans 'eating patterns tend to be westernized and their preference for natural products with certain functionalities is increasing, consumers' demand for mushroom-applied products is expected to grow.

Modern foods, as well as the primary functions that only considered nutrition of the hunger era and the selective secondary functions of taste foods generated in an abundant food environment, as well as the sensory demands caused by the abundance of food, induce predation by diversity and individualization, By causing the imbalance, modern people suffer from new diseases such as adult diseases, and in order to overcome this, there is a demand for a product having a third function of physiological control activity having a bioregulatory function.

Recently, as the economic growth and the dietary life of the rapid industrialization have been westernized, various chronic degenerative diseases are increasing, and among these, the incidence of diabetes (diabetes mellitus) is rapidly increasing in Korea.

In the case of diabetes, complications often occur. When diabetes mellitus occurs, the incidence of atherosclerotic vascular diseases including coronary artery disease, cerebrovascular disease, and peripheral vascular disease is higher than that of the general population. These complications account for%.

Diabetes treatment is treated with insulin and other drugs. However, conventional insulin or oral hypoglycemic drugs are limited in their treatment, and there is a risk of side effects as well as economic burden. On the basis of natural therapy, research is being conducted to explore pharmacological substances such as natural plants, which have been used as folk medicine.

As a countermeasure, the present inventors can replace the administration of insulin or oral hypoglycemic agent and find a new composition that can enhance the efficacy effect. As a result of the composition and research on this, a new chaga extract preparation method was developed using ultrasonic extraction method, and thus a new composition containing chaga extract was formed, and the composition was found to have antidiabetic activity. Completed.

The health food composition having the anti-diabetic activity of the present invention and its manufacturing method have the following technical configuration.

First, the health food having an anti-diabetic activity of the present invention 10 ~ 30% by weight chaga extract, 40 ~ 60% by weight of ginko worm extract, 10-15% by weight of lettuce extract, 10-15% by weight of corn beard extract, root extract 1 It is a health food composition having antidiabetic activity consisting of ~ 10% by weight and 1 ~ 10% by weight of Schisandra chinensis extract. The method for preparing the same is ultrasonically prepared with chaga mushroom at 20 to 50 KHz for 2-3 hours in water, ethanol or a mixture thereof. After extracting, filtration and concentration, 10-30% by weight of the frozen or spray-dried chaga extract, and the remaining herbal medicines such as jinjin, upper leaves, corn beard, brown root and Schizandrae separately at 20-50 KHz for 2-3 hours, Ultrasonic extraction with ethanol or a mixed solution thereof, filtration and concentration, 40-60% by weight of ginko wormwood extract, 10-15% by weight of lettuce leaf extract, 10-15% by weight of corn beard extract, 1-10 Weight percent and Now extract 1 to 10 mixed with one or more acceptable carriers% by weight of chemical agents, by homogenizing a process for preparing a health food composition having anti-diabetic activity.

Chaga mushroom (Inonotus obliquus = Fuscoporia obliquus), belonging to the genus Hynoenochaetaceae, is a mushroom growing in black birch trees growing in the deep mountains above 45 ° north latitudes. Russia Siberia and Canada It is found a lot in Hokkaido region of Japan. Also called fluoride crab mushrooms, birch mushrooms, and trapezoids. Chaga does not form a lampshade, its surface is hard and has a black sheen, and its interior is made of hard cork, which is similar in shape to a situation mushroom. When boiled, the color of the woody mud mushrooms (Phellinus linteus) is golden, whereas the chaga mushroom is blacker golden and has a lighter taste and aroma. The chaga fruit body contains polyphenols, tritelphenoids, tars, and agar. It contains flavonoids, inotodion, alkaloids, polysaccharides, sterin, lignin, and large amounts of manganese. It also contains iron, silicon, aluminum, calcium, magnesium, copper, and zinc. It is known to be used for diabetes.

Among various plant types, especially mushrooms are known to have pharmacological action. In Korea, studies on the physiological activity of various mushroom extracts, such as medicinal mushrooms and edible mushrooms, which are higher mole fungi, are insufficient.

The inventors of the present invention were able to extract chaga mushroom with an extraction efficiency superior to the conventional simple reflux extraction method by using ultrasonic extraction as an extraction method to prepare chaga extract with high physiological activity, and also without loss of the active ingredient in chaga Chaga extract powder having a high stability while maintaining was able to be prepared, and a composition containing this chaga extract was constituted to prepare a new composition.

According to one feature of the present invention, in the extracting means of chaga, a solvent such as water, ethanol, or a mixture thereof can be used as the extraction solvent, and the extraction method uses an ultrasonic extraction method.

The ultrasonic frequency at the time of ultrasonic extraction is set to 20 to 50 KHz, preferably 2 to 3 hours at 25 to 35 KHz, more preferably 28 to 30 KHz.

After filtration through a 75 μm sieve (concentrate) to 1/10 of the amount of 3 times the ethanol was added and left for 12 hours. After the precipitate is formed, the precipitate is collected by filtration, and then dialyzed in running water using a Visking tube for 48 hours, and freeze-dried or spray-dried to prepare chaga extract powder.

Explain about the rest of the herbal medicines, Injin mugwort, lettuce, corn beard, brown root and Schisandra chinensis extract powder.

Injin mugwort extract powder is a dry extract obtained by extracting outposts of Artemisia asiatica Nakai or Artemisia Capillaris belonging to Compositae, and essential oils such as cineol, tujone, vitamins and enzymes. It contains ingredients, and has been used as a diuretic, jaundice, and blood pill since ancient times.

The leaf extract powder is a dry extract obtained by extracting the folium of Morus alba, which belongs to the Moraceae family. Pectin, amyrine, cyanidin, quersetin, etc. Contains glycosides, pigments, etc., and has been used as anti-inflammatory, diuretic, antitussive, and tonic medicine since ancient times.

Corn beard extract powder is a dry extract obtained by extracting the beard (Ok calligraphy or jade water) of corn (Zea Mays Linne) belonging to the family Grmineae. Phytosterol, peroxidase, glucose (Glucose) Contains xylan, galactan, etc., and has been used as a diuretic since ancient times.

Root extract powder is a dry extract obtained from the root of Pueraria Thumbergiana Bentham, which belongs to the legumes (Leguminosae), and it is a diedzein, isoflavone, puerarian, etc. It is contained and has been used as antipyretic and antiperspirant since ancient times.

Schisandra chinensis powder is a dry extract obtained by extracting the ripe fruit (fructus) of Schizandraceae belonging to Schizandraceae, which contains organic acids (Malic acid, tartaric acid), etc. It has been used as astringent, nourishing, tonic medicine, soft drink, and differential.

According to another feature of the present invention, in the extraction means of the herbal medicine of the new composition except chaga, as the extraction solvent, a solution such as water, ethanol, or a mixture thereof can be used, and the extraction method uses ultrasonic extraction.

The ultrasonic frequency at the time of ultrasonic extraction is set to 20 to 50 KHz, preferably 2 to 3 hours at 25 to 35 KHz, more preferably 28 to 30 KHz.

Each herbal extract powder is separately prepared by filtration through a 75 μm sieve and lyophilization or spray drying.

In freeze-drying, the sample is first frozen rapidly at -30 to -50 ° C, and the freeze-dried product obtained by treatment for 48 to 72 hours while maintaining the vacuum at a vacuum of about 1 to 0.1 mmHg is pulverized to 200 mesh.

In the case of spray drying, it is processed by a well-known method in a normal temperature spray dryer.

The composition ratio of chaga mushroom extract constituting the health food composition having antidiabetic activity according to the present invention is 10.0 to 30.0% by weight, preferably 12.0 to 18.0% by weight, based on the total weight of the herbal medicine. If it is less than 10% by weight is not preferable because it does not exhibit the functionality according to the anti-diabetic treatment, when the 30% by weight or more is used is also not preferable because the phenomenon of ring crushing is deteriorated.

Phosphorus mugwort extract is preferably contained 40 to 60% by weight, 40% by weight or less is not desirable because it does not exhibit the functionality for diabetes, at 60% by weight or more due to the phenomenon of sticking to each other during the manufacturing of pills It is also undesirable.

It is preferable to contain 10 to 15% by weight of the lettuce extract and corn beard extract, respectively, but less than 10% by weight does not exhibit the function according to the anticipated treatment for diabetes. The ring breakage occurs due to the decrease, which is also undesirable.

It is preferable to contain 1 ~ 10% by weight of the root extract and Schisandra chinensis extract respectively, 1% by weight or less does not exhibit the functionality for diabetes, and more than 10% by weight in the manufacturing of the pill does not form during manufacture Problems have arisen and are also undesirable.

The herbal composition of the present invention can be formulated by mixing and homogenizing with one or more carriers that are pharmaceutically acceptable, and suitable excipients, stabilizers, sweeteners, pH adjusters, suspending agents, flavoring agents, such as starch, lactose, stevioside, etc. It can be taken orally in the form of granules, tablets, capsules, pills, liquids and the like contained.

The pill provided by this invention follows a conventional manufacturing method.

In other words, the pill of the present invention is precisely weighed jinjin mugwort, upper leaf, corn beard, brown root, Schisandra chinensis extract each herbal medicine in a separate ultrasonic extractor and then freeze-dried to make each herbal extract powder, separately weighing chaga mushrooms ultrasonically Put it in the extractor and extract and freeze-dried to make chaga extract powder.

Each extract powder is mixed, homogenized and refilled to form pills.

The herbal composition of the new composition of the present invention prepared as described above was subjected to acute toxicity, and the formulation was tested for antidiabetic and compared with chaga extract alone.

As a result of comparing the effects on the composition of the present invention, the composition of the present invention showed a superior effect on the anti-diabetic rather than chaga extract alone administration.

In general, the health food of the present invention is recommended to be taken by water 20 times (one dose 120 mg basis) three times a day for adults. Of course, depending on the patient's condition can be increased or decreased.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited thereto.

Example 1 Prescription of a Herbal Composition of the Prescription of the Present Invention.

Chaga Extract Powder 15.0%, Injin Mugwort Extract Powder 50.0%, Leaf Extract Extract 12.5%, Corn Bear Extract Powder 12.5%, Root Extract Powder 5.0%, Schizandra Extract Powder 5.0%

Example 2 Preparation of Extract Powder of the Prescription of the Present Invention

    ① Preparation of Injin mugwort extract powder.

500 g of ginseng cabbage was precisely weighed, and the mixture was added to an ultrasonic extractor, extracted with 2 times the amount of purified water for 2 hours, filtered through a 75 μm sieve, and lyophilized to prepare 120 g of ginseng extract powder.

    ② Preparation of leaf extract powder.

125 g of the upper lobe was precisely weighed and placed in an ultrasonic extractor, extracted with 2 times the amount of purified water for 2 hours, filtered through a 75 μm sieve, and freeze-dried to prepare 30 g of the leaf extract powder.

    ③ Preparation of corn beard extract powder.

125 g of corn beard is precisely weighed, placed in an ultrasonic extractor, extracted with 2 times the amount of purified water for 2 hours, filtered through a 75 μm sieve, and freeze-dried to prepare 30 g of corn beard extract powder.

    ④ Preparation of Root Extract Powder.

41.7 g of fine roots are precisely weighed, placed in an ultrasonic extractor, extracted with 2 times the amount of purified water for 2 hours, filtered through a 75 μm sieve, and lyophilized to prepare 12 g of the extracted root powder.

    ⑤ Preparation of Schizandra chinensis Extract Powder.

41.7 g of Schizandra chinensis pins are precisely weighed, and 10 times of purified water is added thereto, extracted for 2 hours, filtered through a 75 μm sieve, and freeze-dried to prepare 12 g of Schizandra chinensis extract powder.

    ⑥ Preparation of chaga extract powder.

Cut the chaga into a certain size, accurately weigh 167 g, place it in an ultrasonic extractor, add 10 times purified water, extract for 2 hours, filter through 75 μm sieve, concentrate to 1/10 volume, and then triple Ethanol is added and left for 12 hours. After the precipitate is formed, the precipitate is collected by filtration, and then dialyzed in running water for 48 hours using a Visking tube and lyophilized to prepare 36 g of chaga extract powder.

Example 3 Preparation of a Herbal Composition-Containing Pill of a Prescription According to the Present Invention

Chaga extract powder obtained in Example 2 36 g, Injin mugwort extract powder 120 g, leaf extract powder 30 g, corn beard extract powder 30 g, root extract powder 12 g, Schisandra extract powder 12 g precisely weighed into a fed machine and purified water 10 g is added and mixed well, then the pills are prepared using a pill maker and then dried to 60 degrees C or less to form pills. The weight of one ring was prepared at 120 mg.

Example 4 Preparation of Herbal Formula-Containing Liquid Formulation According to the Present Invention

Chaga extract powder obtained in Example 2 36 g, Injin mugwort extract powder 120 g, leaf extract powder 30 g, corn beard extract powder 30 g, root extract powder 12 g, Schisandra extract powder 12 g precisely weighed into purified tank Add 6000 ml and 5 g of stevioside, dissolve and mix well, adjust the total volume to 7000 ml by adding purified water, homogenize by sufficiently stirring, filter with 75 μm sieve, and then 70 ml volume of polyethylene container. Charge was prepared.

Example 5 Preparation of Herbal Composition-Containing Granules According to the Invention

Chaga extract powder obtained in Example 2 36 g, Injin mugwort extract powder 120 g, leaf extract powder 30 g, corn beard extract powder 30 g, root extract powder 12 g, Schizandra extract powder 12 g precisely weighed into a fed 60 g and 20 g of purified water were added and mixed well. Then, granules were made using a granulator, and dried to 60 degrees C or less to make 300 g of granules.

Example 6 Preparation of Herbal Composition-Containing Tablets According to the Present Invention

Chaga extract powder obtained in Example 2 36 g, Injin mugwort extract powder 120 g, leaf extract powder 30 g, corn beard extract powder 30 g, root extract powder 12 g, Schizandra extract powder 12 g precisely weighed into a fed 58 g and 20 g of purified water were added and mixed well. Then, the granules were formed using a granulator, dried to 60 ° C. or less to form granules, and 2 g of magnesium stearate was added thereto. .

Example 7 Preparation of Herbal Formula-Containing Capsules According to the Present Invention

Chaga extract powder obtained in Example 2 36 g, Injin mugwort extract powder 120 g, leaf extract powder 30 g, corn beard extract powder 30 g, root extract powder 12 g, Schizandra extract powder 12 g precisely weighed into a fed 58 g and 20 g of purified water were added and combined well. Then, granules were formed using a granulator, dried to 60 ° C. or less, granules were added thereto, and 2 g of magnesium stearate was added thereto, followed by hard capsule using a hard capsule filler. 500 mg was filled in to prepare a hard capsule.

Experimental Example 1: Stability test of the herbal composition of the prescription according to the present invention

The specimens were prepared using the pills prepared according to Example 3, and the storage conditions were room temperature storage (1-30 ° C., 40-55% RH: long-term storage test), and the storage and observation periods were 6 months and 12 months immediately after preparation. , 18 months, 24 months.

As a result, as follows: ① Property ② Loss on drying ③ Disintegration test ④ Dilute ethanol extract test ⑤ Foreign body test ⑥ For all test items of batch test, it is safe to meet the criteria of each item in room temperature preservation conditions from the time of manufacture to 24 months after manufacture. Confirmed.

① Appearance

   A) Test Criteria: It should be black pills and free of odors and foreign substances.

   B) Test results

② Loss on drying

   A) Standard: Less than 5.0%

   B) Test results

③ Disintegration test

   A) Standard: Within 60 minutes from 1 solution

   B) Test results

④ Dilute ethanol extract test

   A) Standard: 37.1 ~ 45.3%

   B) Test results

⑤ Foreign body test

   A) Test standard: It is a black brown pill, and it should be free of odor and foreign substance.

   B) Test results

⑥ Batch test

   A) Standard: Less than 5.0%

   B) Test results

Experimental Example 2: Acute toxicity test of the herbal composition of the prescription according to the present invention

1. Experimental method

  ① Experiment animal

Sprague-Dawley (SD) rats (180-220 g in weight) were purchased and circulated in the laboratory for about 1 week, then healthy animals were selected. Temperature 23 ± 3 ℃, relative humidity 50 ± 10%, exhaust 10-12 Was bred in an environment of 12 to hr cycles with a fluorescent light intensity of 150 to 160 Lux.

Solid feed and water were adequately supplied during the test period.

  ② Test sample

Example 3 To prepare a pill powder, sodium carboxymethylcellulose was added to purified water according to the experimental dose, and then suspended and used as an experimental sample.

  ③ Dosage

6800 mg / kg dose group, the maximum dose of the new herbal composition, was the highest dose group, and 80 mg / kg dose group was the lowest dose group. ) And a control group, and the administration was prepared orally administered once.

  ④ Observation Items

    1) General symptoms observation

General symptoms for all experimental animals were observed at least once a day for 1 hour to 6 hours after administration and at least once daily for 1 to 14 days after administration. Careful observation was made for the presence of dead animals, and for symptoms likely to be caused by the test substance after administration of the test substance.

    2) weight measurement

All experimental animals used in the test were weighed on the 3rd, 7th, 9th, and 14th day of administration (Day 0).

    3) autopsy

Survival cases after the end of the test was weighed before the autopsy and killed under ether anesthesia (ether), and then visually observed the appearance and internal organ abnormalities in detail.

    4) statistical analysis

Statistical analysis on weight change measured in acute toxicity test was performed by ANOVA (ANOVA) test in case of equal variance, and Student's t-test was tested by p <0.05, p when significance was found in ANOVA test. It was carried out at the <0.01 level.

2. Test result

  ① Observation of dead animals and clinical symptoms

No animals died during the trials in all dose groups. (Table 1). In addition, no symptoms were recognized as toxic by the test substance.

Table 1. Survival rate of Sprague-Dawley rats administered orally with herbal compositions

  ② weight change

No significant body weight change was observed at all doses compared to the control.

  ③ Visual autopsy findings

There were no deaths in the control group and all dose groups, and no gross abnormalities were observed in the surviving individuals.

From the above results, the LD50 value of the new prescription herbal composition was above 6800 mg / kg (about 170 times the dose) of the rats used in this experiment. .

Experimental Example 3: Effect Test of the Herbal Composition of Prescriptions According to the Present Invention

1. Experimental Animal

Sprague-Dawley (SD) rats (120-160 g in weight) were purchased and circulated in the laboratory for about 10 days, and healthy animals were selected. Temperature 23 ± 3 ℃, relative humidity 50 ± 10%, exhaust 10-12 Was bred in an environment of 12 to hr cycles with a fluorescent light intensity of 150 to 160 Lux.

Solid feed and water were adequately supplied during the test period.

2. Preparation of Experimental Solution

  ① Test sample

Example 3 A mixed powder of pills was added, and sodium carboxymethylcellulose was added to purified water according to the experimental dose.

  ② Preparation of streptozotocin solution

500 mg of Streptozotocin (Sigma. U.S.A) was dissolved in 50 ml of 10 mM-cold citrate buffer (pH 4.5) and prepared when used.

3. Experimental method

  ① Induction of hyperglycemia by streptozotocin

   Six females of Sprague-Dawley (SD) mice were fasted for 16 hours before streptozocin administration, and then dissolved in 10 mM-cold citrate buffer (pH 4.5) solution, followed by streptozotocin. ) 45 mg / kg intraperitoneally induce hyperglycemia.

  ② Blood collection and serum separation

    On the 4th day of streptozotocin administration, the rats were fasted for 24 hours before blood collection (water was freely supplied), and then collected from the inferior vena catheter under ether anesthesia, allowed to stand at room temperature for 20 minutes, and then centrifuged at 3,000 rpm for 15 minutes. Serum was separated by separation.

  ③ measurement of blood sugar

    After ether anesthesia, blood was collected from the inferior vena cava and measured immediately using a glucometer and a glucostix.

  ④ Determination of total cholesterol (Cholesterol) content in serum

Serum total cholesterol (Cholesterol) content was measured using Rapid Blood Analyzer <RaBA> and cholesterol (Cholesterol) kit reagent.

  ⑤ Measurement of Triglycerides in Serum

    Serum triglycerides content was measured by U.V. Spectrophotometer and Triglycerides kit kit was used to measure the wavelength at 500 nm.

4. Experimental Results and Discussion

  Experimental results of the composition of the present invention and chaga extract powder alone administration for streptozotocin-induced hyperglycemia are shown in Table 2.

  ① Effect of streptozotocin alone on blood glucose

    The blood sugar level of the normal group was 74 ± 3.52 mg / dl, and the blood sugar level of the control group that induced high blood sugar by the administration of streptozotocin (streptozotocin) was 198.4 ± 13.68 mg / dl. It was enough to induce.

    Serum total cholesterol level was 41.9 ± 2.37 mg / dl in the normal group and 55.7 ± 3.46 mg / dl in the control group. The serum triglyceride level was 93.4 ± 4.56 in the normal group. mg / dl, the control group also showed a significant increase of 129.6 ± 9.25 mg / dl.

  ② Effect of chaga extract powder alone administration on streptozotocin-induced hyperglycemia

     In general, the test group administered with chaga extract powder showed a significant dose-dependent drop in blood glucose compared to the control group administered with streptozotocin only.

    Chaga extract powder 200 mg / kg, 400 mg / kg and 800 mg / kg were administered once a day at 24 hours, 48 hours and 72 hours after injection 30 minutes before streptozotocin injection. As a result, blood glucose levels of these test groups were 102.8 ± 10.82 mg / dl, 77.8 ± 2.55 mg / dl and 66.8 ± 3.95 mg / dl, respectively. The blood glucose level of control group treated with streptozotocin (streptozotocin) was 198.4 ± 13.68 mg / dl, respectively. Compared with the dose-dependently significant blood sugar drop, the Chaga extract powder 800 mg / kg group showed a slightly lower blood sugar level than the normal group's blood sugar level of 74.8 ± 3.52 mg / dl.

    Serum total cholesterol levels of these test groups were 49.9 ± 3.84 mg / dl, 37.6 ± 3.51 mg / dl, and 32.3 ± 2.42 mg / dl, respectively, with 400 mg / kg and 800 mg / kg of Chaga extract powder. In the group, the total cholesterol level of the control group treated with streptozotocin alone was significantly higher than that of 55.7 ± 3.46 mg / dl, and the total cholesterol level of the normal group was 41.9 ± 2.37. The result was slightly lower than mg / dl.

    Triglyceride levels in serum of these test groups were 86.5 ± 5.93 mg / dl, 83.7 ± 5.64 mg / dl, and 82.6 ± 4.99 mg / dl, respectively, of triglycerides of the control group treated with streptozotocin (streptozotocin only). Triglyceride value was 129.6 ± 9.25 mg / dl, which was significantly lower than normal triglyceride value of 93.4 ± 4.56 mg / dl. There was little change in triglycerides.

  ③ Effect of new composition administration on streptozotocin-induced hyperglycemia Looking at the effect on blood glucose, test groups to which the composition of the present invention was administered compared to the control group administered only streptozotocin (streptozotocin) showed a significant hypoglycemic effect. Although the results were somewhat lower than those of the normal group, the blood glucose level was relatively small due to the increase of the dose, and did not show severe hypoglycemia even at the high dose.

     The blood glucose level by administration of the composition 200 mg / kg, 400 mg / kg and 800 mg / kg according to the present invention was 69.8 ± 3.84 mg / dl, 64.7 ± 3.97 mg / dl and 62.9 ± 2.92 mg / dl. streptozotocin) was significantly lower than the blood sugar level of 198.4 ± 13.68 mg / dl in the control group.

     The blood glucose level of 69.8 ± 3.84 mg / dl when administered 200 mg / kg of the composition of the present invention was significantly lower than the blood sugar level of 102.8 ± 10.82 mg / dl when administered alone with 200 mg / kg of chaga extract powder. In addition, compared to the blood glucose level 77.8 ± 2.55 mg / dl when chaga extract powder 400 mg / kg alone administration, the administration of the composition of the present invention was administered twice the dose of chaga extract powder The hypoglycemic effect was increased more than the case.

     The blood sugar level of 64.7 ± 3.97 mg / dl when the composition 400 mg / kg of the present invention is administered is lower than the blood sugar level of 77.8 ± 2.55 mg / dl. The results showed that the 800 mg / kg of chaga extract alone was lower than the blood sugar level of 66.8 ± 3.95 mg / dl, and the administration of the composition of the present invention was higher than that of the chaga extract powder alone. Increased blood sugar lowering effect was shown.

     The blood sugar level of 62.9 ± 2.92 mg / dl when administered 800 mg / kg of the composition of the present invention was lowered by lower blood sugar level than the blood sugar level of 66.8 ± 3.95 mg / dl when administered with 800 mg / kg of chaga extract powder. The results are shown.

The effect of serum on total cholesterol (cholesterol) level, compared to the control group administered only streptozotocin (streptozotocin), the administration group of the composition showed a significant decrease in the total cholesterol (cholesterol) level, even compared to the normal group Although the results were somewhat lower, serum cholesterol lowered slowly as the dose was increased.

The total cholesterol level by administration of 200 mg / kg, 400 mg / kg and 800 mg / kg of the composition of the present invention was 34.1 ± 3.24 mg / dl, 29.5 ± 1.96 mg / dl and 28.7 ± 1.88 mg / dl. The total cholesterol (cholesterol) level of the control group administered with only streptozotocin showed a significant decrease in total cholesterol level compared to 55.7 ± 3.46 mg / dl.

The total cholesterol level of 34.1 ± 3.24 mg / dl when administered 200 mg / kg of the composition of the present invention was significantly higher than the total cholesterol level of 49.9 ± 3.84 mg / dl when chaga extract 200 mg / kg was administered alone. Low, the result was an increase in the total cholesterol (cholesterol) lowering effect, and also lower than the total cholesterol level of 37.6 ± 3.51 mg / dl when chaga extract 400 mg / kg alone, the present invention When the composition was administered, the total cholesterol (cholesterol) level lowering effect was increased than when the two-fold dose of chaga extract was administered alone.

The total cholesterol level of 29.5 ± 1.96 mg / dl when administered to 400 mg / kg of the composition of the present invention was compared to the total cholesterol level of 37.6 ± 3.51 mg / dl when treated with 400 mg / kg of chaga extract alone. Low cholesterol (cholesterol) levels resulted in an increase in serum total cholesterol (cholesterol) lowering effect, and also compared to 32.3 ± 2.42 mg / dl when chaga extract 800 mg / kg alone administration of the present invention In the case of administration of the composition, the total cholesterol (cholesterol) level lowering effect was increased than in the case of administration of double dose of chaga extract alone.

The total cholesterol value of 28.7 ± 1.88 mg / dl of the total cholesterol level of 800 mg / kg of the composition of the present invention was compared to 32.3 ± 2.42 mg / dl of 800 mg / kg of chaga extract alone. Lower serum levels resulted in an increase in total cholesterol (cholesterol) levels.

In the case of chaga extract alone administration, the total cholesterol decreased significantly as the dose was increased, which was significantly lower than the total cholesterol level of 41.9 ± 2.37 mg / dl. During administration, the change was relatively small with increasing dose.

Examining the effect of serum triglycerides (triglycerides), the test group administered the composition of the present invention showed a significant triglycerides lowering effect compared to the control group administered only streptozotocin (streptozotocin), normal group The results were somewhat lower than those of the chaga extract alone.

Triglyceride levels in serum by administration of 200 mg / kg, 400 mg / kg and 800 mg / kg of the composition of the present invention were 82.3 ± 8.76 mg / dl, 81.9 ± 4.98 mg / dl and 80.5 ± 4.86 mg / dl As a result, the streptozotocin-only control group showed a significant lowering effect compared to the triglyceride value of 129.6 ± 9.25 mg / dl.

The triglyceride value of 200 mg / kg of the composition of the present invention was 82.3 ± 8.76 mg / dl, which was lower than that of 86.5 ± 5.93 mg / dl of chaga extract alone.

Triglyceride value 81.9 ± 4.98 mg / dl when the composition 400 mg / kg administration of the present invention is lower than 83.7 ± 5.64 mg / dl when chaga extract 400 mg / kg alone administration lower triglycerides (triglycerides) It showed an increased effect, and also lower than that of 82.6 ± 4.99 mg / dl when chaga extract 800 mg / kg was administered alone, when the composition of the present invention was administered with a double dose of chaga extract alone. Serum triglyceride (triglycerides) lowering than the case showed an increased result.

The triglyceride value of 80.5 ± 4.86 mg / dl when the composition of the present invention was administered 800 mg / kg was lower than that of 82.6 ± 4.99 mg / dl when the Chaga extract 800 mg / kg was administered alone. triglycerides) showed increased results.

Table 2. The composition of the present invention for hyperglycemia in streptozotocin induced rats, the effect of blood glucose levels, serum total cholesterol levels and serum triglycerides levels after administration of chaga extract powder.

The values are mean ± S.E.

*: P <0.05, **: P <0.01 (significantly different from the control value)

From the above experimental results, the administration of the new composition according to the present invention increases the hypoglycemic effect on the blood glucose level, total cholesterol (cholesterol) level and serum triglycerides (triglycerides) level than the case of chaga extract powder alone. Even with increasing doses, blood glucose, total cholesterol and serum triglycerides levels were relatively small, and antidiabetic activity, which can reduce side effects such as hypoglycemia when a large dose was administered alone, was relatively low. Indicated.

Claims (3)

10 to 30% by weight chaga extract, 40 to 60% by weight ginjin extract, 10 to 15% by weight lettuce extract, 10 to 15% by weight corn beard extract, 1 to 10% by weight of brown root extract and 1 to 10% by weight of Schizandra chinensis extract. Health food composition having an antidiabetic effect. Chaga mushrooms were extracted ultrasonically with water, ethanol or a mixture of these for 2-3 hours at 20-50 KHz, filtered and concentrated, and then dried and dried with 10-30% by weight of chaga extract, jinjin mugwort, lettuce, corn beard, brown root and Schisandra chinensis extract was extracted by ultrasonication with water, ethanol or a mixture of these for 2-3 hours at 20 to 50 KHz, 40 to 60% by weight, and 10 to 15% by weight of leaf extracts. , 10 to 15% by weight of corn beard extract, 1 to 10% by weight of brown root extract and 1 to 10% by weight of Schisandra chinensis extract and one or more pharmaceutically acceptable carriers are mixed and homogenized to prepare a health food composition having antidiabetic activity. How to manufacture. The method of claim 2, wherein the formulation is a granule, tablet, capsule, pill or liquid.